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Abstract
A 71-year-old woman presented with constitutional signs and lower extremity palpable
purpura after being prescribed a four-day course of 500 mg of ciprofloxacin two times daily for a
gastrointestinal infection. She was admitted for inpatient treatment. During the third hospital
day, she presented with an episode of abundant hematemesis while her skin lesions remained
unchanged. Upper endoscopy revealed multiple lesions consistent with vasculitis and
histological examination of the skin biopsy disclosed a leukocytoclastic vasculitis. The patient
was successfully treated with prednisone following ciprofloxacin discontinuation. Complete
resolution of the lesions on drug withdrawal strongly suggested drug toxicity, which was
further supported by a score of 8 in the Naranjo Adverse Drug Reaction Probability Scale.
Awareness that the development of skin and gastrointestinal lesions following administration
of ciprofloxacin may be a manifestation of ciprofloxacin-induced vasculitis can help early
detection, treatment, and lead to an overall good prognosis.
Categories: Internal Medicine, Allergy/Immunology, Rheumatology
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Introduction And Background
Ciprofloxacin is a generally safe and extensively used drug in everyday clinical practice only
rarely associated with hypersensitivity reactions. These reactions are largely characterized by
pruritus, rash, or photosensitivity and occur in less than 2% of users [1].
We described a case of an elderly woman with several comorbidities that developed
leukocytoclastic vasculitis (LCV) with cutaneous and gastrointestinal involvement after a four-
day course of ciprofloxacin for the treatment of a gastrointestinal infection. The authors
consider relevant to report this case because, although ciprofloxacin-related cutaneous
vasculitis is rare, the diagnosis can be challenging as the clinical picture may be
indistinguishable from other forms of vasculitis. The diagnosis requires a high degree of
suspicion, particularly due to a possibly fatal outcome. It is important for clinicians to be
alerted to this potential adverse effect that can be easily treated with drug discontinuation.
Additionally, the case presents gastrointestinal involvement, which had been unreported to
date, and was successfully treated with drug withdrawal and glucocorticoid therapy.
1 2 1 2
 Open Access ReviewArticle  DOI: 10.7759/cureus.900
How to cite this article
Morgado B, Madeira C, Pinto J, et al. (November 28, 2016) Leukocytoclastic Vasculitis with Systemic
Involvement Associated with Ciprofloxacin Therapy: Case Report and Review of the Literature. Cureus
8(11): e900. DOI 10.7759/cureus.900
Review
Case report
A 71-year-old overweight woman with no personal or family history of dermatologic
conditions, atopy, or adverse drug reactions presented to her primary care facility with a 12-
hour history of abundant watery diarrhea, together with colic-type abdominal pain, vomiting,
and negative for stool blood, pus, or mucus. Her history was positive for essential hypertension.
She was observed by her primary care provider and was prescribed ciprofloxacin and an oral
saline rehydration formula after which she was discharged. Four days later, she presented to
our emergency department with no symptomatic improvement and complained of new onset
arthralgias, myalgias, fatigue, and lower limb skin lesions described as small, reddish, slightly
pruriginous macules. Her medications included telmisartan, 40 mg daily, hydrochlorothiazide,
12.5 mg daily, and the recently prescribed ciprofloxacin, 500 mg two times daily. She referred to
taking paracetamol, 1 g once to twice a week, for an occasional headache and denied use of any
other over-the-counter or herbal medications. Physical examination was remarkable for signs
of dehydration, a tympanic temperature of 38.3°C, blood pressure of 107/54 mmHg, pulse of
87/min, respiratory rate of 19/min, and pulse oximetry of 98% on ambient air. Abdominal
examination revealed only a slightly tender abdomen on palpation. Neurologic examination
was normal. The skin presented with small, multiple violaceous discolorations of various sizes,
ranging from approximately 1 to 6 mm, visible over the medial and anterior aspect of the lower
part of both lower limbs (Figure 1A-1D). Informed patient consent was obtained at the time of
treatment.
FIGURE 1: Macroscopic view of the main lesions on admission
The lesions cover the anterior and medial aspect of the lower limbs. They are violaceous
discolorations of heterogeneous asymmetric shapes, sharp borders, and of various sizes
ranging from 1 to 6 mm.
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The lesions were non-blanching, tender, and slightly raised on palpation. Femoral and distal
pulses were present, and there was no palpable femoral or inguinal lymphadenopathy as well as
any further dermatological findings. Laboratory analysis disclosed a slight leukocytosis (12.3 x
10 9/L) and a C-reactive protein elevation (63 mg/L), hyperkalaemia (5.65 mmol/L),
hypernatremia (156 mmol/L), elevated blood urea (30 mg/dL), and serum creatinine (1.2
mg/dL). She was admitted on the pretext of dehydration with inability to tolerate oral food or
fluid intake, and the following acute problems were considered:
- Acute gastroenteritis of probable viral aetiology
- Renal impairment of mixed, but mainly pre-renal aetiology
- Electrolytic abnormalities
- Violaceous lesions on lower limbs of unknown aetiology
Oral and intravenous rehydration were undertaken as needed, and ciprofloxacin was not
discontinued as other causes for the presented clinical findings were still being considered.
The day after admission, a skin punch biopsy was performed. In the search for evidence of
systemic disease, further investigations were conducted that revealed no abnormalities in
sedimentation rate, serum complement proteins C3 and C4, immunoglobulin A (IgA),
angiotensin-converting enzyme (ACE), and circulating immunocomplexes. Anti-nuclear
antibodies, antineutrophil cytoplasmic antibody (ANCA), anti-histone antibodies, rheumatoid
factor, and anti-streptolysin-O were also negative. Serology for hepatitis B and C, as well as
HIV, was negative. There was no indication of eosinophilia. After intravenous rehydration
therapy, renal function and serum electrolytes improved and returned to baseline over the
following days.
During the third hospital day, the pruritic lesions showed no signs of improvement and the
patient presented with the sudden onset of hematemesis. Upper endoscopy revealed the
presence of violaceous lesions of variable sizes over the gastric fundus and duodenal bulb,
similar to the presenting skin lesions, and consistent with vasculitis (Figure 2A-2B).
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FIGURE 2: Endoscopic appearance of the gastric lumen
Lesions are observable over the (A) duodenal bulb and (B) gastric fundus, both consistent with
vasculitis.
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Biopsies were not performed so as to avoid inducing further blood loss. Upper endoscopy also
revealed what seemed to have been a significant amount of blood originating from the airway.
Lower endoscopy was also performed and revealed no significant findings. Given the upper
endoscopic findings of blood originating from the airway, plain chest X-ray and high-resolution
computer tomography (CT) were ordered for the suspected respiratory system involvement and
revealed no discernible abnormalities. The patient refused bronchoscopy examination.
Urinalysis and blood culture results were normal, and the rest of the physical examination
showed no evidence of vasculitis involving other organ systems. At this time, the suspicion
arose of systemic vasculitis associated with ciprofloxacin. This was followed by the immediate
discontinuation of the drug. She was given a course of prednisone at a dose of 0.5 mg/kg daily
with gradual improvement of the skin lesions over the following week and no new episodes of
hematemesis. Biopsy of the skin lesions showed areas of LCV with a fragmentation of
neutrophils and red blood cell extravasation. Other areas displayed features of oedema of the
vessel wall and inflammatory infiltration with fibrinoid necrosis (Figure 3A-3B).
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FIGURE 3: Microscopic view of the skin lesions
Leukocytoclastic vasculitis with fragmented neutrophils, red blood cell extravasation, and mild
fibrinoid necrosis of the vascular wall.
We assumed the presence of systemic vasculitis, and no further invasive diagnostic procedures
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Sl
No  Yes No
Do not
know
Score in
this case
1 Are there previous conclusive reports on this reaction? +1 0 0 +1
2 Did the adverse event occur after the suspected drug was administered? +2 -1 0 +2
3 Did the adverse reaction improve when the drug was discontinued or aspecific antagonist was administered? +1 0 0 +1
4 Did the adverse reaction reappear when the drug was re-administered? +2 -1 0 0
5 Are there alternative causes (other than the drug) that could have, on theirown, caused the reaction? -1 +2 0 +2
6 Did the reaction reappear when a placebo was given? -1 +1 0 0
7 Was the drug detected in the blood (or other fluids) in concentrations knownto be toxic? +1 0 0 0
8 Was the reaction more severe when the dose was increased or less severewhen the dose was decreased? +1 0 0 +1
9 Did the patient have a similar reaction to the same or similar drugs in anyprevious exposure? +1 0 0 0
10 Was the adverse event confirmed by any objective evidence? +1 0 0 +1
    Total 8
were performed. We decided to further validate the diagnosis by resorting to the Naranjo
Adverse Drug Reaction (ADR) Probability Scale, commonly used in clinical practice to
determine the likelihood of whether an adverse drug reaction is due to a suspected drug or
other causes (Table 1) [2].
TABLE 1: Naranjo Adverse Drug Reaction (ADR) Probability Scale
Scoring ≥ 9 = definite ADR; 5 - 8 = probable ADR; 1 - 4 = possible ADR; 0 = doubtful ADR.
In our case, the probability of a drug-induced LCV adverse reaction is scored as “probable”
(score 8, with a higher than 8 required for a definitive diagnosis). Given the severity of the
previous clinical picture, we did not consider the possibility of reexposing the patient to the
drug, a key point in many algorithms for a definitive diagnosis but seldom performed in clinical
practice. Thus, by excluding other causes of systemic and gastrointestinal disease, we
concluded that the most probable diagnostic hypothesis in the present case was a
ciprofloxacin-induced cutaneous vasculitis with gastric involvement.
Outcome and follow-up
The patient made a good clinical recovery with complete resolution of diarrhoea and
restoration of normal renal function. Upon discontinuation of the ciprofloxacin, the violaceous
lesions displayed significant progress; within 48 hours, most lesions showed signs of
improvement. There was complete resolution of the skin and gastrointestinal lesions on the
upper endoscopy at 11 days after admission. The patient was discharged without symptoms and
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with almost complete resolution of the skin findings 12 days following admission. The adverse
drug reaction was recorded as a known condition in the patient’s medical record, and assistant
physicians were notified of the present hypersensitivity and the possibility of cross-reaction
with other agents in the same drug class. At follow-up consultations two, six, and 12 months
after discharge, she remained clinically well with all observations within the normal range.
Discussion
Following evaluation of the patient’s clinical history, laboratory and physical examination
findings, a drug-induced cutaneous vasculitis was suspected with ciprofloxacin as the culprit.
The time between first exposure to the drug and the onset of the first clinical findings range
from three days to five weeks. This reaction appears to be reported in first-time users of the
drug as well as with patients who took ciprofloxacin beforehand with no history of drug-
induced vasculitis [3-12].
LCV is an uncommon but potentially serious side effect of ciprofloxacin. It is a small-vessel
vasculitis characterized histologically by leukocytoclasis and presenting cardinal features, such
as palpable, violaceous papules, affecting most commonly the lower part of the legs. Other
manifestations, such as fever, arthralgias, lymphadenopathy, and an elevated erythrocyte
sedimentation rate, are present in most patients [13-14]. The exact mechanism of LCV remains
unknown but is thought to be the result of a type III hypersensitivity reaction with deposition
of immune complexes and consequent damage to blood vessels by neutrophils [15]. Schmid, et
al. mentioned that quinolones can cause hypersensitivity reactions through several different
pathophysiological mechanisms [16]. The clarification of such mechanisms may change our
understanding of how to prevent this reaction in some patients.
There is a paucity of reports in the literature regarding cutaneous LCV with or without systemic
involvement association with ciprofloxacin therapy. From 1989 to date, we found only 13 case
reports of LCV related to ciprofloxacin use (Table 2) [3-12].
2016 Morgado et al. Cureus 8(11): e900. DOI 10.7759/cureus.900 8 of 12
Dose
Time to
clinical
onset
Other
medications
Diagnostic
method
Affected
organ-
systems
Final diagnosis Treatment Yearpublished
500 mg
po BID 3 days None Skin biopsy Cutaneous
Mononuclear-
cell infiltrate
Removal of
ciprofloxacin 1989
[4]
500 mg
po QD 4 days Cephradine Skin biopsy Cutaneous LCV
Removal of
ciprofloxacin 1992
[11]
Unknown 10 days Diuretic Clinical Cutaneous Haemorrhagicvasculitis None 1992
[11]
Unknown 4 days Unknown Skin biopsy Cutaneous Mononuclear-cell infiltrate
Removal of
ciprofloxacin 1994
[8]
500 mg
po BID 4 days Fluoxetine Clinical Cutaneous
Cutaneous
vasculitis
Removal of
ciprofloxacin 1997
[6]
375 mg Unknown Ceftriaxone
Skin biopsy
and
rechallenge
test
Cutaneous LCV
Removal of drug and
negative ceftriaxone
challenge test
1997[5]
Unknown Unknown
Oral
antidiabetic,
nifedipine and
digoxin
Clinical and
skin biopsy
Cutaneous
and renal
vasculitis
LCV Removal of drug andprednisone treatment 2001
[7]
Unknown 3 days Several drugs Skin biopsy Cutaneous LCV Removal ofciprofloxacin 2004
[12]
Unknown 10 days None Clinical andbiopsy
Cutaneous
and renal
vasculitis
Cutaneous and
renal vasculitis
Removal of drug and
prednisone treatment 2007
[9]
Unknown 7 days Rifampin Clinical Cutaneous Drug-inducedvasculitis
Removal of
ciprofloxacin 2009
[3]
Unknown 10 days Flucloxacillin Clinical Cutaneous Drughypersensitivity
Removal of
ciprofloxacin 2009
[3]
500 mg
po BID 4 days Clindamycin Clinical Cutaneous
Haemorrhagic
vasculitis
Removal of
ciprofloxacin 2010
[10]
400 mg
IV BID 6 days Clindamycin Clinical Cutaneous
Haemorrhagic
vasculitis
Removal of
ciprofloxacin 2010
[10]
TABLE 2: Prior Case Reports of Ciprofloxacin-induced Vasculitis
LCV: leukocytoclastic vasculitis 
They described patients with a variety of clinical presentations, mostly presenting cutaneous
LCV and constitutional signs, and a few provided confirmation of additional organ system
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damage. Of these, two cases reported LCV with renal involvement and only Storsley, et al.
confirmed renal vasculitis with biopsy [7, 9]. To the extent of our knowledge, the literature does
not mention any case of ciprofloxacin-related vasculitis with gastrointestinal involvement [3-
12]. Even though renal vasculitis with ciprofloxacin-induced LCV is rare, and gastrointestinal
involvement has not been documented, drug-induced LCV is known to involve several systems,
including the lungs and gastrointestinal tract [17-21]. Pace, et al. described systemic vasculitis
with cutaneous, gastric, and renal involvement with the use of ofloxacin, another quinolone
[22]. Likewise, Ceyhan, et al. reported an ofloxacin-induced vasculitis affecting the stomach and
colon that presented clinically with bloody diarrhoea [23]. This is consistent with our patient
presenting with hematemesis and endoscopic findings consistent with vasculitis following
seven days of treatment. Not performing a gastric biopsy prevents us from making an accurate
diagnosis of gastric involvement in our patient. Nevertheless, based on the clinical evidence of
hematemesis, skin biopsy, and upper endoscopic findings before and after drug removal, we are
confident that the gastric and duodenal mucosa presented with histologically similar lesions to
the ones found on the skin, all attributable to treatment with ciprofloxacin.
Every patient believed to suffer from cutaneous vasculitis should undergo a detailed history,
physical, and laboratory assessment. Diagnosing cutaneous vasculitis requires determination of
the calibre of the vessels involved. Punch biopsy should be the method of choice since, as
mentioned, LCV affects small vessels and the nature of the inflammatory infiltrate
(neutrophilic, lymphocytic, or granulomatous) is one of the main factors considered for
diagnosis. Since the composition of the infiltrate changes rapidly, an early biopsy is best if a
reliable diagnosis is to be made [24]. Establishing the relationship between the offending agent
and LCV is accomplished clinically and by the evident relationship between drug exposure and
clinical presentation [25]. Some laboratory findings, such as ANCA and anti-histone antibodies,
are occasionally helpful in the diagnosis of drug-induced vasculitis [9].
Cross-reactivity for the development of maculopapular exanthema with one fluoroquinolone
predicts a recurrence with another fluoroquinolone for a small percentage of patients. Ball, et
al. predicted a 10.4% probability of rash recurrence when taking ciprofloxacin in women who
previously developed an exanthema with gemifloxacin. In the same study, several female
patients who initially tolerated ciprofloxacin developed a rash when the treatment was again
repeated with the same drug [26]. Even though cross-reactivity between ciprofloxacin and other
quinolones have been described with the development of delayed-onset maculopapular
cutaneous eruptions, to our knowledge, only one case has suggested an LCV resultant from
cross-reactivity between quinolones. Blyth, et al. reported an LCV related with levofloxacin in a
patient previously exposed to ciprofloxacin, raising the possibility of cross-reactivity reactions
between quinolones, which can extend to full-blown LCV [24].
Owing to the rare nature of the phenomenon, no specific directives exist in managing
ciprofloxacin-induced systemic LCV. Martinez-Taboada, et al. stated that discontinuation of
the offending agent usually leads to resolution of the signs and symptoms in drug-induced LCV
within days to weeks without the need of additional treatment. Some patients with joint
symptoms may require non-steroidal anti-inflammatory drugs. Patients with a chronic or
systemic disease may benefit from prednisone therapy. A minority of patients has been
reported to require the addition of immunosuppressive agents, such as azathioprine or
cyclophosphamide, to prednisone [27]. Most patients with this condition have a benevolent
course following drug withdrawal, which should usually allow physicians to avoid overtreating
these patients. Nevertheless, Pace, et al. described a case of fatal vasculitis associated with
ofloxacin, and several reports have been made for drug-induced vasculitis with poor outcomes
[18, 22]. In view of the knowledge currently available, and considering the age, comorbidities,
and systemic involvement which was particular to our patient, pre-emptive glucocorticoid
therapy was deemed appropriate for 10 days. This proved to be adequate and consistent with
other cases, as treatment duration for all patients in the reported cases ranged from four to 10
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days [3-12].
Even though the safety profile of quinolones is similar to other classes of antibacterial
agents, severe low-frequency adverse drug hypersensitivity reactions, which may include
vasculitis, have occurred with a small number of specific quinolones, namely, ciprofloxacin,
ofloxacin, and levofloxacin [24]. Ciprofloxacin is overall a well-tolerated and widely used drug
that has been available for more than 25 years for the treatment of a multitude of bacterial
infections [1]. The most common adverse effects reported involve the gastrointestinal tract,
with less than 8% of patients experiencing side effects, such as nausea, vomiting, and
diarrhoea. Central nervous system involvement is less common, with less than 6.4% of users
enduring effects, such as headaches and dizziness. Only as few as 3.6% of patients go on to
experience phototoxicity and hypersensitivity reactions in which vasculitis is included [28].
Conclusions
Consistent with preceding case reports linking the use of ciprofloxacin to LCV, we consider the
former drug as the probable cause of LCV in our patient. Our patient presented with systemic
vasculitis that included cutaneous and gastrointestinal involvement, which is unreported to
date. Review of the current literature suggests the possibility of a cross-reaction between
quinolones in causing LCV. As with previous case reports, our patient made a full recovery with
prednisone treatment and removal of ciprofloxacin. While this condition is generally benign, it
is important to recognize drug-induced LCV as it can be fatal without timely drug withdrawal.
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